Superworth

TG Therapeutics EV/EBIT TGTX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Nov 2, 2026
68.7×
3-year median
58.1×
Against its 3-year history
72nd
percentile: 0 is its lowest day, 100 its highest
3-year range
32.4× to 161×
Peer median
58.4×

TG Therapeutics' EV/EBIT is 68.7× as of Nov 2, 2026.

That is above its 3-year median of 58.1×, higher than on 72% of days in the last 3 years.

Over that time it ranged from 32.4× in Sep 2024 to 161× in May 2025.

The median for 10 large drugmakers of a similar size is 58.4×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far68.7×37.0×70.1×
202548.6×48.6×161×
202439.8×32.4×129×

Against its peers

Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.

Where TG Therapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on TG Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.